[{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"Orexin-2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DSP-0390","moa":"EBP","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo \/ Pfizer Inc"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sumitomo

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.

                          Product Name : SEP-363856

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 15, 2024

                          Lead Product(s) : Ulotaront

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : $30.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.

                          Product Name : Gemtesa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 09, 2023

                          Lead Product(s) : Vibegron

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.

                          Product Name : Myfembree

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : Relugolix,Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

                          Product Name : SEP-363856

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 31, 2023

                          Lead Product(s) : Ulotaront

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis.

                          Product Name : TP-3654

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2022

                          Lead Product(s) : TP-3654

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : TP-1287 is enzymatically cleaved, yielding active moiety, potent inhibitor of CDK9. Inhibiting CDK9 is thought to downregulate transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies...

                          Product Name : TP-1287

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2022

                          Lead Product(s) : TP-1287

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : DSP-0390 is an investigational emopamil-binding protein (EBP) inhibitor. EBP is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.

                          Product Name : DSP-0390

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 18, 2022

                          Lead Product(s) : DSP-0390

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...

                          Product Name : JZP441

                          Product Type : Other Small Molecule

                          Upfront Cash : $50.0 million

                          April 05, 2022

                          Lead Product(s) : DSP-0187

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Jazz Pharmaceuticals

                          Deal Size : $1,140.0 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has shown potential antitumor and anti-fibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.

                          Product Name : TP-3654

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 11, 2022

                          Lead Product(s) : TP-3654

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank